Lilly Puerto Rico plant sold to Colombia drugmaker

A surplus Eli Lilly plant in Puerto Rico has a new owner, which intends to invest more than $90 million in upgrades and hire 350 workers.

On Tuesday, Lilly ($LLY) confirmed an Associated Press report that the company sold the plant in Guayama to Bogota, Colombia-based Laboratorios Biogen SA, which is not to be confused with U.S.-based Biogen.

Biogen SA intends to invest $92 million updating the facility, where it will manufacture APIs. The company is receiving $2 million in incentives from the government for the project, Gov. Alejandro Garcia Padilla told the news service, and intends to hire 350 workers within the next 5 years.  

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Lilly announced in 2014 that it would close the plant in Guayama by the end of 2015, but was offering jobs to its 100 employees at a plant in Carolina about 50 miles away. Lilly said at the time it would take a $170 million charge to cover the costs of shuttering the Guayama facility.

The Carolina plant had benefited from $240 million in investments as part of Lilly’s buildup in insulin products. In November 2013, the facility was tagged with receiving a $200 million investment to increase its insulin API capacity and then in the next year got another $40 million for some oral solid-dosage work.

Related Articles: 
Lilly will close Puerto Rico plant, affecting 100 workers 
Lilly to invest $700M in plant expansions

Suggested Articles

Higher operating costs were behind a 17% slide in pretax profits last year at Allergan’s Mayo, Ireland, facility that produces Botox.

After a global scare over Zantac contamination, generic metformin could be next in line as regulators test for possible carcinogen contamination.

PCI Pharma Services debuts expansion of its plant in Rockford, Illinois.